Biogen's Alzheimer's Disease Treatment Earns FDA Approval
The long wait for a disease-modifying treatment option for millions of Americans suffering from Alzheimer's disease is finally over. The FDA on Monday approved aducanumab from Biogen (NASDAQ: BIIB) and its longtime collaboration partner Eisai (OTC: ESALY). Biogen will market the drug under the brand name Aduhelm.
Aduhelm acts in the brain to remove amyloid protein fragments before they can form sticky plaques associated with Alzheimer's disease. Unfortunately, aducanumab failed to outperform a placebo in one of two identical clinical trials designed to prove its ability to help preserve patients' cognitive ability. Biogen also failed to convince a panel of independent experts that Aduhelm provided a disease-modifying benefit.
Image source: Getty Images.
Source Fool.com
